A new study sponsored by Bayer is looking at how mobile digital devices can be integrated into the clinical trial experience.
“Our hopes are to create a better experience for all involved with our clinical trials while enhancing our data collection efforts,” Michelle Shogren, portfolio and operations innovation manager at Bayer, said in a statement. “By listening to the patient’s voice, we have the ability to improve our study designs of the future and ultimately help patients get the medicines they need.”
The devices for the first phase were an activity monitor and a linked scale. Once feedback came in the researchers decided to add a cloud solution for data uploads.
While not specifically stated in the story, this hints that data management needs to be made extremely simple for patients in order to get good results from any mHealth studies or products. Wise marketers will heed this message.
Other stories from MobiHealthNews:
- Roundup: Digital health pharma news of Q1 2018
- FDA permits marketing of AI software that autonomously detects diabetic retinopathy
- Study: App for mindful meditation had the same effect as sham meditation app
- FDA reneged on its promise to take a risk-based approach to CDS software
- Fitbit, UnitedHealth, Empatica heads discuss data privacy challenges for wearables
- Study: App accurately tracks Parkinson’s disease symptoms
